keyword
MENU ▼
Read by QxMD icon Read
search

Apheresis stem cells

keyword
https://www.readbyqxmd.com/read/29134688/neutropenic-fever-during-peripheral-blood-progenitor-cell-mobilization-is-associated-with-decreased-cd34-cell-collection-and-increased-apheresis-collection-days
#1
Jack Khouri, Lisa Rybicki, Navneet Majhail, Matt Kalaycio, Edward Copelan, Brad Pohlman, Brian Hill, Robert Dean, Aleksandr Lazaryan, Betty Hamilton, Steven Andresen, Ronald Sobecks, Brian Bolwell, Hien Liu
BACKGROUND: Peripheral blood progenitor cell (PBPC) mobilization with chemotherapy in addition to Granulocyte-Colony Stimulating Factor (G-CSF) improves cell collection compared to G-CSF alone; however, it is associated with increased risk of neutropenic fever (NF). METHODS: We analyzed risk factors for post-priming NF and NF association with autologous stem cell transplant outcomes. Between 1998 and 2008, 593 adult patients with lymphoma underwent PBPC mobilization with etoposide and G-CSF...
November 14, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/29132746/diabetes-mellitus-as-a-poor-mobilizer-condition
#2
REVIEW
Gian Paolo Fadini, John F DiPersio
Hematopoietic stem cell (HSC) transplantation in an effective and curative therapy for numerous hematological malignancies. Mobilization of HSCs from bone marrow (BM) to peripheral blood (PB) followed by apheresis is the gold standard for obtaining HSCs for both autologous and allogeneic stem cell transplantation. After administration of granulocyte-colony stimulating factor (G-CSF), up to 30% of patients fail to mobilize "optimal" numbers of HSCs required for engraftment. This review summarizes the current experimental and clinical evidence that diabetes mellitus is a risk factor for poor mobilization...
November 8, 2017: Blood Reviews
https://www.readbyqxmd.com/read/29123428/hematopoietic-stem-cell-transplantation-in-a-severe-refractory-crohn-s-disease-patient-with-intestinal-stoma-a-case-report
#3
Milton Artur Ruiz, Roberto Luiz Kaiser Junior, Luiz Gustavo de Quadros, Gustavo Henrique Xavier Caseiro, Aderson Francisco Oliveira, Tatiana Peña-Arciniegas, Lilian Piron-Ruiz, Fernanda Soubhia Liedtke Kaiser, Vera Lucia Oliveira
Background: Hematopoietic stem cell transplantation (HSCT) can be used in the treatment of patients with refractory Crohn's disease (CD) when no alternative treatment is available. However, HSCT increases the risk of infections, in particular during the aplasia of mobilization and conditioning. Moreover, intestinal stomas in CD augment the risk of morbidity in immunocompromised patients and under aplastic conditions. The objective of this report was to describe the results of the first year after HSCT in a CD patient with an intestinal stoma...
2017: International Medical Case Reports Journal
https://www.readbyqxmd.com/read/29035394/infusion-of-autograft-natural-killer-cell-cd14-hla-dr-dim-cell-ratio-predicts-survival-in-lymphoma-post-autologous-stem-cell-transplantation
#4
A Kansagra, D J Inwards, S M Ansell, I N Micallef, P B Johnston, W J Hogan, S N Markovic, L F Porrata
The infusion of autograft absolute lymphocyte count (A-ALC) and autograft natural killer cells (A-NKC) are prognostic factors for overall survival (OS) and PFS in non-Hodgkin's lymphoma (NHL) patients undergoing autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT). The human monocytic CD14(+)HLA-DR(DIM) cells are associated with worse prognosis in NHL. Thus, we investigated whether the autograft A-NKC/A-CD14(+)HLA-DR(DIM) ratio predicts survival in NHL. In a total of 111 NHL patients, we analyzed apheresis collection samples for the content of A-NKC and A-CD14(+)HLA-DR(DIM)...
October 16, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28980709/current-strategies-for-the-management-of-autologous-peripheral-blood-stem-cell-mobilization-failures-in-patients-with-multiple-myeloma
#5
REVIEW
Ugur Sahin, Taner Demirer
Multiple myeloma (MM) is the leading indication of autologous hematopoietic stem cell transplantation (AHSCT) worldwide. The collection of PBSCs is the essential step for AHSCT. The limits for minimum and optimum CD34(+) cells collected have been accepted as 2 × 10(6) /kg and ≥4 × 10(6) /kg for single AHSCT; 4 × 10(6) /kg and ≥8-10 × 10(6) /kg for double AHSCT. Despite the success of conventional methods for PBSC mobilization in MM, mobilization failure is still a concern depending on patient age, duration of disease, and the type of induction therapy...
October 5, 2017: Journal of Clinical Apheresis
https://www.readbyqxmd.com/read/28935952/application-of-bio-orthogonal-proteome-labeling-to-cell-transplantation-and-heterochronic-parabiosis
#6
Yan Liu, Michael J Conboy, Melod Mehdipour, Yutong Liu, Thanhtra P Tran, Aaron Blotnick, Prasanna Rajan, Thalie Cavalcante Santos, Irina M Conboy
Studies of heterochronic parabiosis demonstrated that with age, the composition of the circulatory milieu changes in ways that broadly inhibit tissue regenerative capacity. In addition, local tissue niches have age-specific influences on their resident stem cells. Here we use bio-orthogonal proteome labeling for detecting in vivo proteins present only in transplanted myoblasts, but not in host tissue, and proteins exclusive to one young mouse and transferred during parabiosis to its old partner. We use a transgenic mouse strain that ubiquitously expresses a modified tRNA methionine synthase, metRS, which preferentially incorporates the methionine surrogate azido-nor-leucine (ANL) into newly generated proteins...
September 21, 2017: Nature Communications
https://www.readbyqxmd.com/read/28935847/cd56-bright-natural-killer-regulatory-cells-in-filgrastim-primed-donor-blood-or-marrow-products-regulate-chronic-graft-versus-host-disease-the-canadian-blood-and-marrow-transplant-group-randomized-0601-study-results
#7
Amina Kariminia, Sabine Ivison, Bernard Ng, Jacob Rozmus, Susanna Sung, Avani Varshney, Mahmoud Aljurf, Sylvie Lachance, Irwin Walker, Cindy Toze, Jeff Lipton, Stephanie J Lee, Jeff Szer, Richard Doocey, Ian Lewis, Clayton Smith, Naeem Chaudhri, Megan K Levings, Raewyn Broady, Gerald Devins, David Szwajcer, Ronan Foley, Sara Mostafavi, Steven Pavletic, Donna A Wall, Stephan Couban, Tony Panzarella, Kirk R Schultz
Randomized trials have conclusively shown higher rates of chronic graft-versus-host disease with filgrastim-stimulated apheresis peripheral blood as a donor source than unstimulated bone marrow. The Canadian Blood and Marrow Transplant Group conducted a phase 3 study of adults who received either filgrastim-stimulated apheresis peripheral blood or filgrastim-stimulated bone marrow from human leukocyte antigen-identical sibling donors. Because all donors received the identical filgrastim dosing schedule, this study allowed for a controlled evaluation of the impact of stem cell source on development of chronic graft-versus-host disease...
November 2017: Haematologica
https://www.readbyqxmd.com/read/28864336/analysis-of-transfusion-related-acute-lung-injury-and-possible-transfusion-related-acute-lung-injury-reported-to-the-french-hemovigilance-network-from-2007-to-2013
#8
REVIEW
Georges Andreu, Karim Boudjedir, Jean-Yves Muller, Elodie Pouchol, Yves Ozier, Guillaume Fevre, Chantal Gautreau, Jean-François Quaranta, Christian Drouet, Claire Rieux, Paul-Michel Mertes, Benoit Clavier, Monique Carlier, Imad Sandid
Using the French Hemovigilance Network database from 2007 to 2013, we provide information on demographics, incidence, and risk factors of reported transfusion-related acute lung injury (TRALI) and possible TRALI, analyze TRALI mitigation efforts for fresh frozen plasma and platelet concentrates, and consider the impact of platelet additive solutions on TRALI incidence. We applied the Toronto consensus conference definitions for TRALI and possible TRALI. Two TRALI subgroups were considered: "antibody positive" when a donor has human leukocyte antigen (class I or II) and/or human neutrophil antigen antibodies and the recipient has cognate antigen, and "antibody negative" when immunological investigation is negative or not done...
July 15, 2017: Transfusion Medicine Reviews
https://www.readbyqxmd.com/read/28833874/use-of-granulocyte-transfusions-among-haematology-units-in-england-and-north-wales
#9
S Morton, A Mijovic, D I Marks, J Griffin, E Massey, N Bhatnagar, S J Stanworth
OBJECTIVES: To establish the current use of granulocyte transfusions in haematology patients and explore interest in further research. BACKGROUND: Granulocytes may be used for the treatment of severe infection in neutropenic patients or for primary or secondary prophylaxis. Clinical utility of granulocyte transfusions is unclear, and recent studies have demonstrated equivocal outcomes. Pooled granulocytes are the main granulocyte product used in England and Wales, but there are no data on the patterns of use and little consensus on accepted indications...
August 18, 2017: Transfusion Medicine
https://www.readbyqxmd.com/read/28830891/autoimmune-hit-due-to-apheresis-catheter-heparin-flushes-for-stem-cell-harvesting-before-autotransplantation-for-myeloma
#10
Hira Mian, Theodore E Warkentin, Jo-Ann I Sheppard, Anna MacDonald, Lori-Ann Linkins, Ann Benger, Ronan Foley
No abstract text is available yet for this article.
August 22, 2017: Blood
https://www.readbyqxmd.com/read/28809049/evolution-of-mnc-and-lymphocyte-collection-settings-employing-different-spectra-optia-%C3%A2-leukapheresis-systems
#11
M Punzel, A Kozlova, A Quade, A H Schmidt, R Smith
BACKGROUND AND OBJECTIVES: The Spectra Optia(®) continuous mononuclear cell (CMNC apheresis) system has emerged as the preferred device in peripheral blood stem cell collections over the original two-step Spectra Optia(®) mononuclear cell (MNC apheresis) system. Until now, no comparative data were available for non-stimulated MNC collections that are required for immunotherapy. MATERIALS AND METHODS: We compared collection parameters and product composition for Spectra Optia MNC- as well as CMNC-apheresis systems in non-stimulated MNC collections from 35 registry donors intended for donor lymphocyte infusions...
August 2017: Vox Sanguinis
https://www.readbyqxmd.com/read/28808609/optimizing-peripheral-blood-stem-cells-transplantation-outcome-through-amend-relapse-and-graft-failure-a-review-of-current-literature
#12
REVIEW
Saeed Mohammadi, Amir Hossein Norooznezhad, Ashraf Malek Mohammadi, Hajar Nasiri, Mohsen Nikbakht, Najmaldin Saki, Mohammad Vaezi, Kamran Alimoghaddam, Ardeshir Ghavamzadeh
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has been considered as a valuable approach in treatment of numerous malignant and none malignant hematologic disorders. However, relapse and poor graft function (PGF) after allo-SCT remain to be controversial issues which may affect the transplantation outcome. Relevant articles were searched in MEDLINE database (2000-2016) using keywords and phrases: donor lymphocyte infusions, allogeneic stem cells transplantation, relapsed hematologic malignancies, booster schedules, cell dose, laboratory monitoring protocols and technical aspects of apheresis...
2017: Experimental Hematology & Oncology
https://www.readbyqxmd.com/read/28801752/biosimilar-g-csf-versus-filgrastim-and-lenograstim-in-healthy-unrelated-volunteer-hematopoietic-stem-cell-donors
#13
Roiya Farhan, Elżbieta Urbanowska, Hanna Zborowska, Małgorzata Król, Maria Król, Tigran Torosian, Iwona Piotrowska, Krzysztof Bogusz, Kamila Skwierawska, Wiesław Wiktor-Jędrzejczak, Emilian Snarski
The World Marrow Donor Organization recommends original granulocyte-colony stimulating factor (G-CSF) for the mobilization of stem cells in healthy unrelated hematopoietic stem cell donors. We report the comparison of a biosimilar G-CSF (Zarzio) with two original G-CSFs (filgrastim and lenograstim) in mobilization in unrelated donors. We included data of 313 consecutive donors who were mobilized during the period from October 2014 to March 2016 at the Medical University of Warsaw. The primary endpoints of this study were the efficiency of CD34+ cell mobilization to the circulation and results of the first apheresis...
October 2017: Annals of Hematology
https://www.readbyqxmd.com/read/28800741/erythrocyte-depletion-from-bone-marrow-performance-evaluation-after-50-clinical-scale-depletions-with-spectra-optia-bmc
#14
Soo-Zin Kim-Wanner, Gesine Bug, Juliane Steinmann, Salem Ajib, Nadine Sorg, Carolin Poppe, Milica Bunos, Eva Wingenfeld, Christiane Hümmer, Beate Luxembourg, Erhard Seifried, Halvard Bonig
BACKGROUND: Red blood cell (RBC) depletion is a standard graft manipulation technique for ABO-incompatible bone marrow (BM) transplants. The BM processing module for Spectra Optia, "BMC", was previously introduced. We here report the largest series to date of routine quality data after performing 50 clinical-scale RBC-depletions. METHODS: Fifty successive RBC-depletions from autologous (n = 5) and allogeneic (n = 45) BM transplants were performed with the Spectra Optia BMC apheresis suite...
August 11, 2017: Journal of Translational Medicine
https://www.readbyqxmd.com/read/28797783/results-of-a-prospective-randomized-open-label-noninferiority-study-of-tbo-filgrastim-granix-versus-filgrastim-neupogen-in-combination-with-plerixafor-for-autologous-stem-cell-mobilization-in-patients-with-multiple-myeloma-and-non-hodgkin-lymphoma
#15
Pavan Kumar Bhamidipati, Mark A Fiala, Brenda J Grossman, John F DiPersio, Keith Stockerl-Goldstein, Feng Gao, Geoffrey L Uy, Peter Westervelt, Mark A Schroeder, Amanda F Cashen, Camille N Abboud, Ravi Vij
Autologous hematopoietic stem cell transplantation (auto-HSCT) improves survival in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). Traditionally, filgrastim (Neupogen; recombinant G-CSF) has been used in as a single agent or in combination with plerixafor for stem cell mobilization for auto-HSCT. In Europe, a biosimilar recombinant G-CSF (Tevagrastim) has been approved for various indications similar to those of reference filgrastim, including stem cell mobilization for auto-HSCT; however, in the United States, tbo-filgrastim (Granix) is registered under the original biological application and is not approved for stem cell mobilization...
August 7, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28675459/stimulation-of-adrenergic-activity-by-desipramine-enhances-hematopoietic-stem-and-progenitor-cell-mobilization-along-with-g-csf-in-multiple-myeloma-a-pilot-study
#16
Aditi Shastri, Anjali Budhathoki, Stefan K Barta, Noah Kornblum, Olga Derman, Ramakrishna Battini, Radha Raghupathy, Amit K Verma, Paul S Frenette, Ira Braunschweig, Murali Janakiram
Hematopoietic stem cell (HSC) release is positively regulated by the sympathetic nervous system through the β3 adrenergic receptor. Preclinical studies have demonstrated that the combination of desipramine and G-CSF resulted in improved HSC mobilization. Here, we present the results of an open-label single-arm pilot study in patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) to assess the safety and efficacy of desipramine combined with G-SCF to induce HSC mobilization. The primary endpoint was safety of the combination including engraftment kinetics...
October 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28653370/multicenter-study-to-evaluate-a-new-enumeration-method-for-hematopoietic-stem-cell-collection-management
#17
MULTICENTER STUDY
Monique Grommé, Henk Russcher, Eric Braakman, J Henriëtte Klinkspoor, Johan A Dobber, Inge de Greef, Norbert C J de Wit
BACKGROUND: CD34 flow cytometry is the gold standard for stem cell enumeration in peripheral blood at the mobilization stage and in the final apheresis product. The new stem cell mode of the Sysmex XN Series analyzer enumerates an immature cell population in the white progenitor and pathological cell (WPC) channel, based on the cell size, internal cellular complexity, and fluorescence intensity. STUDY DESIGN AND METHODS: In this multicenter study we analyzed 147 peripheral blood samples, 22 samples during collection of stem cells, and 45 samples from the apheresis product of 18 healthy allogeneic donors and 84 autologous patients...
August 2017: Transfusion
https://www.readbyqxmd.com/read/28647402/autologous-stem-cell-transplantation-in-patients-with-multiple-myeloma-an-activity-based-costing-analysis-comparing-a-total-inpatient-model-versus-an-early-discharge-model
#18
Massimo Martino, Giuseppe Console, Letteria Russo, Antonella Meliado', Nicola Meliambro, Tiziana Moscato, Giuseppe Irrera, Giuseppe Messina, Antonella Pontari, Fortunato Morabito
BACKGROUND: Activity-based costing (ABC) was developed and advocated as a means of overcoming the systematic distortions of traditional cost accounting. MATERIALS AND METHODS: We calculated the cost of high-dose chemotherapy and autologous stem cell transplantation (ASCT) in patients with multiple myeloma using the ABC method, through 2 different care models: the total inpatient model (TIM) and the early-discharge outpatient model (EDOM) and compared this with the approved diagnosis related-groups (DRG) Italian tariffs...
August 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28647301/factors-affecting-hematopoietic-stem-cell-mobilization-and-apheresis-in-allogeneic-donors-the-role-of-iron-status
#19
Zübeyde Nur Özkurt, Leyla Batmaz, Zeynep Arzu Yeğin, Çiğdem İlhan
Infused CD34 cell count has a significant impact on transplant outcome. In this retrospective study, we aimed to analyze the impact of donor iron parameters on peripheral blood stem cell (PBSC) collection. A total of 303 related donors were included in the study. The mobilization regimen, recombinant G-CSF, was given for four consecutive days. A CD34(+) cell count below 2×10(6)/kg was defined as mobilization failure which was demonstrated in 23 donors (7.6%). Mobilization failure was more frequent in female donors than male donors (13...
June 3, 2017: Transfusion and Apheresis Science
https://www.readbyqxmd.com/read/28631842/uk-consensus-statement-on-the-use-of-plerixafor-to-facilitate-autologous-peripheral-blood-stem-cell-collection-to-support-high-dose-chemoradiotherapy-for-patients-with-malignancy
#20
Kenneth W Douglas, Maria Gilleece, Patrick Hayden, Hannah Hunter, Peter R E Johnson, Charlotte Kallmeyer, Ram K Malladi, Shankara Paneesha, Rachel Pawson, Michael Quinn, Kavita Raj, Deborah Richardson, Stephen Robinson, Nigel Russell, John Snowden, Anna Sureda, Eleni Tholouli, Kirsty Thomson, Mike Watts, Keith M Wilson
Plerixafor is a CXC chemokine receptor (CXCR4) antagonist that mobilizes stem cells in the peripheral blood. It is indicated (in combination with granulocyte-colony stimulating factor [G-CSF]) to enhance the harvest of adequate quantities of cluster differentiation (CD) 34+ cells for autologous transplantation in patients with lymphoma or multiple myeloma whose cells mobilize poorly. Strategies for use include delayed re-mobilization after a failed mobilization attempt with G-CSF, and rescue or pre-emptive mobilization in patients in whom mobilization with G-CSF is likely to fail...
June 20, 2017: Journal of Clinical Apheresis
keyword
keyword
41980
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"